Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
49.54
-0.11 (-0.22%)
At close: Apr 28, 2026, 4:00 PM EDT
49.39
-0.16 (-0.31%)
After-hours: Apr 28, 2026, 7:42 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 51.4, with a low estimate of 42 and a high estimate of 63. The average target predicts an increase of 3.75% from the current stock price of 49.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $51 → $57 | Strong Buy | Maintains | $51 → $57 | +15.06% | Apr 21, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $61 → $63 | Buy | Maintains | $61 → $63 | +27.17% | Apr 10, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $48 → $50 | Strong Buy | Maintains | $48 → $50 | +0.93% | Jan 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | -9.16% | Dec 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $54 | Buy | Maintains | $55 → $54 | +9.00% | Oct 10, 2025 |
Financial Forecast
Revenue This Year
3.30B
from 2.38B
Increased by 38.63%
Revenue Next Year
3.45B
from 3.30B
Increased by 4.73%
EPS This Year
5.17
from 1.78
Increased by 190.09%
EPS Next Year
5.54
from 5.17
Increased by 7.15%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.6B | 4.0B | ||||||
| Avg | 3.3B | 3.5B | ||||||
| Low | 2.6B | 2.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 52.8% | 20.7% | ||||||
| Avg | 38.6% | 4.7% | ||||||
| Low | 8.4% | -21.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 5.51 | 6.14 | |||||
| Avg | 5.17 | 5.54 | |||||
| Low | 4.30 | 4.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 209.4% | 18.9% | |||||
| Avg | 190.1% | 7.1% | |||||
| Low | 141.5% | -12.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.